2023-503734-47-00已完成1 期
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813, a growth hormone antagonist, in healthy subjects
Amolyt Pharma, Amolyt Pharma1 个研究点 分布在 1 个国家目标入组 101 人开始时间: 2023年4月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 101
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Principal Investigator - ICON
Scientific
Amolyt Pharma
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A study in healthy subjects to see the effects of the test medicine ALKS 2680 in single and multi-dose regimePhase 1 drug studyNervous System DiseasesISRCTN98204977Alkermes (United States)147
招募中
1 期
A single- and multiple ascending dose study of KP-910 in healthy adult males and healthy elderly males.JPRN-jRCT2071230041Murakami Harumi96
已完成
1 期
Phase 1 study of BAY 3283142 in Japanese healthy male participantsChronic kidney diseaseJPRN-jRCT2071230002Myoishi Masafumi36
招募中
1 期
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.ACTRN12620000583943Senz Oncology Pty Ltd50
已完成
1 期
A single-dose ascending study and a multiple-dose study in healthy male subjects and a multiple-dose study in subjects who have no more than 3 spontaneous bowel movements per week to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of DSP-6952, and a single-dose study in healthy male subjects to examine the effect of food.jRCT2080223728Sumitomo Dainippon Pharma Co., Ltd.96